Hydroxyzine Pamoate 50 mg Capsule, 50-count — NDC 60687-707-65 (Billing 60687-0707-65)
This is a package of 50 capsules of Hydroxyzine Pamoate 50 mg Capsule from American Health Packaging, marketed since May 2023 and currently FDA-listed; retail pharmacies pay about $0.0820 per capsule (NADAC). It is the main listing for this product, which comes in 2 package sizes.
NDC database record
One package, one record: these facts belong to NDC 60687-707-65 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 60687 labeler · 707 product · 65 package
- Package marketed since
- Dec 21, 2023
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Billing quantity
- 50 EA per package
- Barcode (UPC-A, from the NDC)
- 3 6068770765 5
- Medicaid fills, this package
- 1,646 prescriptions in the last four reported quarters
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 003732
- GCN: 13953
- HICL (First Databank): 001609
- AHFS class code: 04:04.00.00
- RxCUI (RxNorm): 995253
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 3, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
RxNorm drug class
This medicine belongs to the Antihistamine class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
Hydroxyzine is used to relieve itching caused by allergic skin reactions, to relieve anxiety and tension, and as a sedative before and after general anesthesia for surgery. Hydroxyzine is in a class of medications called antihistamines. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms. It also works by decreasing activity in the brain.
Read the full MedlinePlus article ↗- Taken by mouth, it's used for anxiety and tension, itching from allergic skin conditions like hives and eczema, and sedation around anesthesia. The injection has additional uses in...
- It can. Drowsiness is the most common effect, though it often fades in a few days or with a lower dose. Don't drive or use dangerous machinery until you know how it affects you.
- It's best not to. Hydroxyzine can strengthen alcohol, narcotics, barbiturates and other sedating drugs. Tell your prescriber about everything you take, since doses of some may need...
- Can I drink alcohol or take other sedating medicines with it?
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 3, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.082 | $4.10 / 50 capsule |
| Medicaid paysCMS SDUD · 12 mo | $1.10 | $54.89 / 50 capsule |
| Medicare drug plans payPart D · Q2 2026 | $0.1145 | $5.73 / 50 capsule |
Where does this data come from?
- CMS NADAC weekly file · file of Sep 30, 2026
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q1 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Marketing end | Status |
|---|---|---|---|---|---|---|
| 60687-0707-01 60687-707-01 | 100 BLISTER PACK in 1 CARTON / 1 CAPSULE in 1 BLISTER PACK | $0.0820 / ea | $8.20 | 2023-05-24 | — | Active |
| 60687-0707-65 You're viewing this Main listing | 50 BLISTER PACK in 1 CARTON / 1 CAPSULE in 1 BLISTER PACK | $0.0820 / ea | $4.10 | 2023-12-05 | — | Active |
This pack effectively ties for the lowest per-ea cost of the 2 priced pack sizes ($0.0820 NADAC).
In Medicaid, this is the most-dispensed pack of this product — about 87% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 60687-0707-01?
What NDC number is used to bill for this package of Hydroxyzine Pamoate 50 mg Capsule?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Hydroxyzine Pamoate 50 mg 00115-1804-01 | Amneal | 100 capsules | $0.082 | AB | Availability likely | — |
| Hydroxyzine pamoate 50 mg 00185-0676-01 | Sandoz | 100 capsules | $0.082 | AB | Availability likely | — |
| Hydroxyzine Pamoate 50 mg 00555-0302-02 | Teva | 100 capsules | $0.082 | AB | Availability likely | — |
| hydroxyzine pamoate 50 mg 14539-0675-01 | Heritage | 100 capsules | $0.082 | AB | Availability likely | — |
| Hydroxyzine Pamoate 50 mg 50268-0399-50 | AvPAK | 50 capsules | $0.082 | AB | Availability likely | — |
| Hydroxyzine Pamoate 50 mgthis 60687-0707-65 | American | 50 capsules | $0.082 | AB | Availability likely | — |
| Hydroxyzine pamoate 50 mg 62135-0817-12 | Chartwell | 120 capsules | $0.082 | AB | Availability likely | — |
| Hydroxyzine Pamoate 50 mg 00615-8420-39 | NCS | 30 capsules | — | AB | FDA listed | — |
| Hydroxyzine pamoate 50 mg 50090-5933-01 | A-S | 20 capsules | — | AB | FDA listed | — |
| hydroxyzine pamoate 50 mg 50090-7540-00 | A-S | 12 capsules | — | AB | FDA listed | — |
| hydroxyzine pamoate 50 mg 51407-0002-01 | Golden | 100 capsules | — | AB | FDA listed | — |
| Hydroxyzine Pamoate 50 mg 51655-0252-52 | Northwind | 30 capsules | — | AB | FDA listed | — |
| Hydroxyzine pamoate 50 mg 66267-0556-90 | NuCare | 90 capsules | — | AB | FDA listed | — |
| Hydroxyzine pamoate 50 mg 67046-0831-03 | Coupler | 30 capsules | — | AB | FDA listed | — |
| hydroxyzine pamoate 50 mg 68071-3583-09 | NuCare | 90 capsules | — | AB | FDA listed | — |
| hydroxyzine pamoate 50 mg 68788-8789-03 | Preferred | 30 capsules | — | AB | FDA listed | — |
| Hydroxyzine pamoate 50 mg 70518-3232-00 | REMEDYREPACK | 60 capsules | — | AB | Discontinued | — |
| hydroxyzine pamoate 50 mg 70518-4463-00 | REMEDYREPACK | 21 capsules | — | AB | FDA listed | — |
| hydroxyzine pamoate 50 mg 71335-1265-01 | Bryant | 30 capsules | — | AB | FDA listed | — |
| Hydroxyzine Pamoate 50 mg 71335-1923-01 | Bryant | 30 capsules | — | AB | FDA listed | — |
| Hydroxyzine pamoate 50 mg 71335-2076-01 | Bryant | 30 capsules | — | AB | FDA listed | — |
| Hydroxyzine Pamoate 50 mg 72189-0315-90 | DirectRx | 90 capsules | — | AB | FDA listed | — |
| Hydroxyzine Pamoate 50 mg 72189-0480-30 | Direct_Rx | 30 capsules | — | AB | FDA listed | — |
| Hydroxyzine Pamoate 50 mg 76420-0921-01 | Asclemed | 100 capsules | — | AB | FDA listed | — |
| hydroxyzine pamoate 50 mg 82868-0046-30 | Northwind | 30 capsules | — | AB | FDA listed | — |
| Hydroxyzine pamoate 50 mg 87441-0041-01 | Unit | 30 capsules | — | AB | FDA listed | — |
| Hydroxyzine pamoate 50 mg 87441-0042-01 | Unit | 500 capsules | — | AB | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file · file of Sep 30, 2026
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
What it looks like
Where does this data come from?
- FDA label on DailyMed · label index refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII M28OL1HH48
Croscarmellose sodium is a plant-based substance derived from cellulose. It acts as a disintegrant, helping tablets and capsules break down quickly in the digestive system so the medicine can be absorbed.
-
UNII 9DBA0SBB0L
A synthetic red dye derived from coal tar used as a colorant in medicines and cosmetics. It gives tablets, capsules, and liquids their red or pink appearance for identification and visual appeal.
-
UNII 35SW5USQ3G
A synthetic yellow dye used to color medicines. It helps make tablets, capsules, and liquids visually distinct so patients can easily identify their medication.
-
UNII H3R47K3TBD
FD&C Blue No. 1 is a synthetic blue dye approved for use in foods and medicines. It serves as a colorant to give the medication its distinctive appearance and help with product identification.
-
UNII L06K8R7DQK
A synthetic blue dye approved by the FDA for use in medications and foods. It serves as a colorant to make pills and liquids visually distinct and easier to identify.
-
UNII WZB9127XOA
A synthetic red dye used to color medications and make them easier to identify. It serves as a colorant in tablets, capsules, and liquid formulations.
-
UNII H77VEI93A8
A synthetic yellow dye used to color medications. It helps identify the drug and make it visually distinctive, with no effect on how the medicine works.
-
UNII XM0M87F357
A dark iron oxide compound that gives medicines their black or dark color. It's used as a colorant in tablets and capsules to help identify the product and make it visually distinctive.
-
UNII 2G86QN327L
Gelatin is a protein derived from animal collagen, commonly used in medicines as a gelling agent and capsule material. It helps create soft or hard capsule shells that hold and release medication, and can also thicken liquid formulations.
-
UNII EWQ57Q8I5X
Lactose monohydrate is a natural sugar derived from milk. It serves as a filler and binder in tablets and capsules, helping create the proper size, texture, and consistency of the medicine.
-
UNII 70097M6I30
Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
-
UNII 6DC9Q167V3
Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
-
UNII 46N107B71O
Shellac is a natural resin secreted by the lac beetle. It's used as a coating on tablets and capsules to control how quickly the medicine dissolves and to improve appearance and stability.
-
UNII O8232NY3SJ
A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.
-
UNII 15FIX9V2JP
Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.
15 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 3, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from American Health Packaging labeler code 60687
- Lacosamide 200 mg Tablet, Film Coated NDC 60687-698-57
- Cefdinir 300 mg Capsule NDC 60687-699-21
- Bethanechol Chloride 25 mg Tablet NDC 60687-700-01
- Glipizide 10 mg Tablet NDC 60687-701-01
- Lamotrigine 200 mg Tablet NDC 60687-704-01
- Demeclocycline Hydrochloride 300 mg Tablet NDC 60687-705-65
- Propafenone Hydrochloride 150 mg Tablet, Film Coated NDC 60687-709-01
- Guanfacine Hydrochloride 1 mg Tablet NDC 60687-710-21
- Oxcarbazepine 150 mg Tablet, Film Coated NDC 60687-711-01
- Fenofibrate 200 mg Capsule NDC 60687-713-21
- Chlorhexidine Gluconate, 0.12% Oral Rinse 1.2 mg/mL Solution NDC 60687-714-16
- Colestipol Hydrochloride 1 g Tablet, Film Coated NDC 60687-715-21
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, hydroxyzine may potentiate meperidine (Demerol ® ) and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis.
Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies.
The physician should reassess periodically the usefulness of the drug for the individual patient.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: in adults, 50 to 100 mg four times a day; children under 6 years, 50 mg daily in divided doses; and over 6 years, 50 to 100 mg daily in divided doses. For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus: in adults, 25 mg three times a day or four times a day; children under 6 years, 50 mg daily in divided doses; and over 6 years, 50 to 100 mg daily in divided doses.
As a sedative when used as a premedication and following general anesthesia: 50 to 100 mg in adults, and 0.6 mg/kg in children. When treatment is initiated by the intramuscular route of administration, subsequent doses may be administered orally. As with all medications, the dosage should be adjusted according to the patient’s response to therapy.
⛔ Contraindications ▾
CONTRAINDICATIONS Hydroxyzine, when administered to the pregnant mouse, rat, and rabbit, induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range. Clinical data in human beings are inadequate to establish safety in early pregnancy. Until such data are available, hydroxyzine is contraindicated in early pregnancy.
Hydroxyzine is contraindicated in patients with a prolonged QT interval. Hydroxyzine pamoate is contraindicated for patients who have shown a previous hypersensitivity to any component of this medication. Hydroxyzine is contraindicated in patients with known hypersensitivity to hydroxyzine products, and in patients with known hypersensitivity to cetirizine hydrochloride or levocetirizine hydrochloride.
⚠️ Warnings ▾
WARNINGS Nursing Mothers It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Side effects reported with the administration of hydroxyzine pamoate are usually mild and transitory in nature. Skin and Appendages Oral hydroxyzine hydrochloride is associated with Acute Generalized Exanthematous Pustulosis (AGEP) and fixed drug eruptions in postmarketing reports. Anticholinergic Dry mouth.
Central Nervous System Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of the dose. Involuntary motor activity, including rare instances of tremor and convulsions, has been reported, usually with doses considerably higher than those recommended. Clinically significant respiratory depression has not been reported at recommended doses.
Cardiac System QT prolongation, Torsade de Pointes. In postmarketing experience, the following additional undesirable effects have been reported: Body as a Whole allergic reaction. Nervous System headache.
Psychiatric hallucination. Skin and Appendages pruritus, rash, urticaria. To report SUSPECTED ADVERSE REACTIONS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
🧓 Geriatric Use ▾
Geriatric Use A determination has not been made whether controlled clinical studies of hydroxyzine pamoate included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy.
The extent of renal excretion of hydroxyzine pamoate has not been determined. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections. Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses of hydroxyzine pamoate and observed closely.
🆘 Overdosage ▾
OVERDOSAGE The most common manifestation of overdosage of hydroxyzine pamoate is hypersedation. Other reported signs and symptoms were convulsions, stupor, nausea and vomiting. As in the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken.
If vomiting has not occurred spontaneously, it should be induced. Immediate gastric lavage is also recommended. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated.
Hypotension, though unlikely, may be controlled with intravenous fluids and vasopressors (do not use epinephrine as hydroxyzine counteracts its pressor action). Caffeine and Sodium Benzoate Injection, USP, may be used to counteract central nervous system depressant effects. Hydroxyzine overdose may cause QT prolongation and Torsade de Pointes.
ECG monitoring is recommended in cases of hydroxyzine overdose. There is no specific antidote. It is doubtful that hemodialysis would be of any value in the treatment of overdosage with hydroxyzine.
However, if other agents such as barbiturates have been ingested concomitantly, hemodialysis may be indicated. There is no practical method to quantitate hydroxyzine in body fluids or tissue after its ingestion or administration.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Hydroxyzine pamoate is unrelated chemically to the phenothiazines, reserpine, meprobamate, or the benzodiazepines. Hydroxyzine pamoate is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the central nervous system. Primary skeletal muscle relaxation has been demonstrated experimentally.
Bronchodilator activity, and antihistaminic and analgesic effects have been demonstrated experimentally and confirmed clinically. An antiemetic effect, both by the apomorphine test and the veriloid test, has been demonstrated. Pharmacological and clinical studies indicate that hydroxyzine in therapeutic dosage does not increase gastric secretion or acidity and in most cases has mild antisecretory activity.
Hydroxyzine is rapidly absorbed from the gastrointestinal tract and hydroxyzine pamoate's clinical effects are usually noted within 15 to 30 minutes after oral administration.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Hydroxyzine pamoate capsules, USP (hydroxyzine pamoate, USP equivalent to hydroxyzine hydrochloride), 25 mg are available as light yellow opaque cap and pink opaque body filled with yellow powder, imprinted in black ink stylized “barr” over “323” on one piece and “25” on the other piece, packaged in: Unit dose packages of 100 (10 x 10) NDC 60687-696-01 Hydroxyzine pamoate capsules, USP (hydroxyzine pamoate, USP equivalent to hydroxyzine hydrochloride), 50 mg are available as light yellow opaque cap and maroon opaque body filled with yellow powder, imprinted in black ink stylized “barr” over “302” on one piece and “50” on the other piece, packaged in: Unit dose packages of 50 (5 x 10) NDC 60687-707-65 Unit dose packages of 100 (10 x 10) NDC 60687-707-01.
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. FOR YOUR PROTECTION: Do not use if blister is torn or broken. Keep this and all medications out of the reach of children.
📋 Description ▾
DESCRIPTION Hydroxyzine pamoate, USP is designated chemically as 1-(p-chlorobenzhydryl) 4-[2-(2-hydroxyethoxy) ethyl] diethylenediamine salt of 1,1′-methylene bis (2 hydroxy-3-naphthalene carboxylic acid). It has the following structural formula: Hydroxyzine pamoate capsules, USP are administered in doses equivalent to 25 mg, 50 mg or 100 mg of hydroxyzine hydrochloride. In addition, each capsule contains the following inactive ingredients: croscarmellose sodium, magnesium stearate, and pregelatinized corn starch.
The 25 mg also contains anhydrous lactose. The 50 mg and 100 mg also contain lactose monohydrate. The capsule shell ingredients for the 25 mg capsule are D&C Red No.
28, D&C Yellow No. 10, FD&C Blue No. 1, FD&C Red No.
40, FD&C Yellow No. 6, gelatin, and titanium dioxide. The 50 mg capsule shell contains D&C Red No.
33, D&C Yellow No. 10, FD&C Yellow No. 6, gelatin, and titanium dioxide.
The 100 mg capsule shell contains D&C Red No. 28, D&C Red No. 33, D&C Yellow No.
10, FD&C Blue No. 1, FD&C Red No. 40, gelatin, and titanium dioxide.
The edible imprinting ink on the 25 mg, 50 mg and 100 mg capsules contains black iron oxide, D&C Yellow No. 10 aluminum lake, FD&C Blue No. 1 aluminum lake, FD&C Blue No.
2 aluminum lake, FD&C Red No. 40 aluminum lake, propylene glycol, and shellac glaze. Structural Formula
⚠️ Precautions ▾
PRECAUTIONS THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES. Therefore, when central nervous system depressants are administered concomitantly with hydroxyzine, their dosage should be reduced. Since drowsiness may occur with use of the drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery while taking hydroxyzine pamoate.
Patients should be advised against the simultaneous use of other CNS depressant drugs, and cautioned that the effect of alcohol may be increased. QT Prolongation/Torsade de Pointes (TdP) Cases of QT prolongation and Torsade de Pointes have been reported during postmarketing use of hydroxyzine. The majority of reports occurred in patients with other risk factors for QT prolongation/TdP (pre-existing heart disease, electrolyte imbalances or concomitant arrhythmogenic drug use).
Therefore, hydroxyzine should be used with caution in patients with risk factors for QT prolongation, congenital long QT syndrome, a family history of long QT syndrome, other conditions that predispose to QT prolongation and ventricular arrhythmia, as well as recent myocardial infarction, uncompensated heart failure, and bradyarrhythmias. Caution is recommended during the concomitant use of drugs known to prolong the QT interval. These include Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, certain antipsychotics (e.g., ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine), certain antidepressants (e.g., citalopram, fluoxetine), certain antibiotics (e.g., azithromycin, erythromycin, clarithromycin, gatifloxacin, moxifloxacin); and others (e.g., pentamidine, methadone, ondansetron, droperidol).
Acute Generalized Exanthematous Pustulosis (AGEP) Hydroxyzine may rarely cause acute generalized exanthematous pustulosis (AGEP), a serious skin reaction characterized by fever and numerous small, superficial, non-follicular, sterile pustules, arising within large areas of edematous erythema. Inform patients about the signs of AGEP, and discontinue hydroxyzine at the first appearance of a skin rash, worsening of pre-existing skin reactions which hydroxyzine may be used to treat, or any other sign of hypersensitivity.
If signs or symptoms suggest AGEP, use of hydroxyzine should not be resumed and alternative therapy should be considered. Avoid cetirizine or levocetirizine in patients who have experienced AGEP or other hypersensitivity reactions with hydroxyzine, due to the risk of cross-sensitivity. Geriatric Use A determination has not been made whether controlled clinical studies of hydroxyzine pamoate included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects.
Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy. The extent of renal excretion of hydroxyzine pamoate has not been determined.
Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections. Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses of hydroxyzine pamoate and observed closely.
🍼 Nursing Mothers ▾
Nursing Mothers It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers.
📄 Package Label / Principal Display Panel ▾
Package/Label Display Panel – Carton – 25 mg NDC 60687- 696 -01 HydrOXYzine Pamoate Capsules, USP 25 mg 100 Capsules (10 x 10) Rx Only Each Capsule Contains: Hydroxyzine pamoate, USP equivalent to 25 mg of hydroxyzine hydrochloride. Usual Dosage: See full prescribing information. Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
FOR YOUR PROTECTION: Do not use if blister is torn or broken. The drug product contained in this package is from NDC # 0555-0323, Teva Pharmaceuticals. Distributed by: American Health Packaging, Columbus, Ohio 43217 769601 0469601/1023 25 mg Hydroxyzine Pamoate Capsules Carton
Package/Label Display Panel – Blister – 25 mg HydrOXYzine Pamoate Capsule, USP 25 mg 25 mg Hydroxyzine Pamoate Capsule Blister
Package/Label Display Panel – Carton – 50 mg, 50 UD NDC 60687- 707 -65 HydrOXYzine Pamoate Capsules, USP 50 mg 50 Capsules (5 x 10) Rx Only Each Capsule Contains: Hydroxyzine pamoate, USP equivalent to 50 mg of hydroxyzine hydrochloride. Usual Dosage: See full prescribing information. Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
FOR YOUR PROTECTION: Do not use if blister is torn or broken. The drug product contained in this package is from NDC # 0555-0302, Teva Pharmaceuticals. Distributed by: American Health Packaging, Columbus, Ohio 43217 770765 0470765/1023 50 mg Hydroxyzine Pamoate Capsules Carton-50UD
Package/Label Display Panel – Carton – 50 mg, 100 UD NDC 60687- 707 -01 HydrOXYzine Pamoate Capsules, USP 50 mg 100 Capsules (10 x 10) Rx Only Each Capsule Contains: Hydroxyzine pamoate, USP equivalent to 50 mg of hydroxyzine hydrochloride. Usual Dosage: See package insert for full prescribing information. Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
Keep this and all drugs out of reach of children. FOR YOUR PROTECTION: Do not use if blister is torn or broken. The drug product contained in this package is from NDC # 0555-0302, Teva Pharmaceuticals.
Distributed by: American Health Packaging Columbus, Ohio 43217 770701 0470701/0923 50 mg Hydroxyzine Pamoate Capsules Carton-100UD
Package/Label Display Panel – Blister – 50 mg HydrOXYzine Pamoate Capsules. USP 50 mg 50 mg Hydroxyzine Pamoate Capsule Blister